The use of protease inhibitors during acute haemorrhagic pancreatitis. Experimental findings and clinical implications.
D000208:Acute Disease; D000818:Animals; D007611:Aprotinin / Q000008:administration & dosage / Q000627:therapeutic use*; D004285:Dogs; D010450:Endopeptidases / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D007610:Kallikreins / Q000097:blood / Q000378:metabolism; D007704:Kininogens / Q000378:metabolism; D007705:Kinins / Q000097:blood; D010179:Pancreas / Q000201:enzymology / Q000378:metabolism; D010195:Pancreatitis / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D011480:Protease Inhibitors; D011498:Protein Precursors
D007704:Kininogens; D007705:Kinins; D011480:Protease Inhibitors; D011498:Protein Precursors; D007611:Aprotinin; D010450:Endopeptidases; D007610:Kallikreins